Welcome to our dedicated page for TC BioPharm (Holdings) plc American Depositary Shares news (Ticker: TCBP), a resource for investors and traders seeking the latest updates and insights on TC BioPharm (Holdings) plc American Depositary Shares stock.
TC BioPharm (Holdings) PLC (NASDAQ: TCBP) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative immunotherapy products. The company leverages its proprietary allogeneic gamma-delta T (GD-T) cell platform to create novel therapies aimed at treating cancer and viral infections.
Gamma-delta T cells are unique immune cells that possess characteristics of both the innate and adaptive immune systems, enabling them to distinguish between healthy and diseased tissues. TC BioPharm's approach uses these cells to develop effective treatments for various cancers, including both liquid and solid tumors.
Notable achievements include the initiation of phase 2b/3 pivotal trials for OmnImmune® in the treatment of acute myeloid leukemia (AML) using their proprietary allogeneic CryoTC technology, which allows for the distribution of frozen cell products to clinics worldwide. The company also maintains a robust pipeline targeting solid tumors and has built a significant intellectual property portfolio.
Recent developments highlight TC BioPharm's dynamic progress:
- March 1, 2024: CEO Bryan Kobel featured on 'The Big Biz Show,' discussing the company's ongoing advancements.
- March 18, 2024: An institutional investor exercised warrants resulting in a net cash infusion of $1.17M, strengthening the company’s financial position.
- March 19, 2024: The company adjourned its General Meeting to gather additional information for a shareholder vote.
- April 2, 2024: Announcement of a new streamlined manufacturing process to increase patient treatment capacity and reduce costs by 85%.
- April 4, 2024: Execution of a non-binding letter of intent to acquire assets focused on CAR-NK cell therapies, enhancing their cancer treatment capabilities.
- May 6, 2024: Agreement for the immediate exercise of certain warrants, raising approximately £3.1M for clinical trials and operations.
- May 6, 2024: Announcement of a second letter of intent to acquire a company developing CAR-T therapies for solid tumors and autoimmune diseases.
- May 15, 2024: Launch of a compassionate use program in the UK for TCB-008, providing new treatment options for patients ineligible for clinical trials.
TC BioPharm continues to focus on expanding its therapeutic platform, leveraging strategic partnerships, and advancing its clinical trials, all while upholding its commitment to improving patient outcomes.
Rhea-AI Summary
TC BioPharm (NASDAQ: TCBP) CEO and Process Development Manager to Speak at 7th CAR-TCR Summit Europe
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
-
Rhea-AI Summary
TC BioPharm (NASDAQ: TCBP) announces shareholder update with projected outlook for 2024, highlighting $11.6M cost savings, FDA clearance for Phase 1B study in AML, collaborations, and milestone achievements. The Company filed a preliminary proxy statement for potential shareholder approval of issuing shares for non-public offerings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.05%
Tags
-
Rhea-AI Summary
TC BioPharm (TCBP) CEO Bryan Kobel featured in live interview with 'Big Biz Show' to discuss the company's allogeneic gamma-delta T cell therapies for cancer. The interview will be aired on cable TV, streaming services, and radio in 175 countries, with podcasts available on various platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.38%
Tags
Rhea-AI Summary
TC BioPharm (Holdings) PLC, a clinical stage biotechnology company, is set to participate in the Sequire Investor Summit 2024. The company's CEO will conduct in-person one-on-one meetings and deliver a presentation on January 24 at 1:30 PM ET. TC BioPharm is focused on developing allogeneic gamma-delta T cell therapies for cancer and other indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.28%
Tags
-
Rhea-AI Summary
TC BioPharm (Holdings) PLC (NASDAQ: TCBP) regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market after its common shares maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive business days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
-
Rhea-AI Summary
TC BioPharm (Holdings) PLC (NASDAQ: TCBP) is implementing cost-saving measures to reduce cash burn by approximately 50% and extend its financial runway, with a focus on advancing its lead therapeutic to the nearest data inflection point, specifically the ACHIEVE trial interim review. The company plans to scale down research and development, implement a focused manufacturing platform, and streamline its organization, resulting in a reduction of headcount by approximately 50%. These initiatives are aimed at driving efficiency and prioritizing clinical success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.2%
Tags
Rhea-AI Summary
TC BioPharm (Holdings) plc (NASDAQ: TCBP) closed a public offering of 1,750,000 of its American Depositary Shares (ADSs) and Series E warrants, raising $3.5 million. The proceeds will fund a clinical trial focusing on relapse/refractory Acute Myeloid Leukemia and continuing operating expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
-
Rhea-AI Summary
TC BioPharm (Holdings) plc (NASDAQ: TCBP) announced the pricing of a public offering of 1,750,000 of its American Depositary Shares (ADSs) at a public offering price of $2.00 per ADS, along with Series E warrants to purchase up to 1,750,000 of its ADSs. The Series E Warrants will have an exercise price of £1.5814 per ADS and will expire five years following the date of issuance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.87%
Tags
-
Rhea-AI Summary
TC BioPharm (Holdings) PLC (NASDAQ: TCBP) announced the creation of a new Commercial Development Division, headed by Dr. Lauren Bor, PhD. The division will focus on optimizing production of TCB-008 in anticipation of ACHIEVE data in 2024 and preparing a clear regulatory path for commercialization. Additionally, it will explore new opportunities with third parties to monetize the company's production capabilities using the GMP licensed facility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
Rhea-AI Summary
TC BioPharm (Holdings) PLC (NASDAQ: TCBP) announced a change in the ratio of its American Depositary Shares (ADSs) to ordinary shares from 1:1 to 1:20. This change is expected to become effective on a specified date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.08%
Tags
FAQ
What is the current stock price of TC BioPharm (Holdings) plc American Depositary Shares (TCBP)?
The current stock price of TC BioPharm (Holdings) plc American Depositary Shares (TCBP) is $0.6239 as of November 22, 2024.
What is the market cap of TC BioPharm (Holdings) plc American Depositary Shares (TCBP)?
The market cap of TC BioPharm (Holdings) plc American Depositary Shares (TCBP) is approximately 343.8K.
What does TC BioPharm (Holdings) PLC specialize in?
TC BioPharm specializes in developing allogeneic gamma-delta T cell therapies for treating various cancers and viral infections.
What are gamma-delta T cells?
Gamma-delta T cells are immune cells that combine properties of the innate and adaptive immune systems, allowing them to effectively identify and target diseased tissues.
What is OmnImmune®?
OmnImmune® is TC BioPharm's therapeutic product currently in phase 2b/3 pivotal trials for treating acute myeloid leukemia (AML) using their proprietary allogeneic CryoTC technology.
How does TC BioPharm's CryoTC technology work?
CryoTC technology enables the company to freeze and distribute allogeneic gamma-delta T cell products to clinics worldwide, ensuring accessibility and efficacy.
What recent financial milestones has TC BioPharm achieved?
An institutional investor recently exercised warrants, providing a net cash infusion of $1.17M. Additionally, the company raised approximately £3.1M through the immediate exercise of certain outstanding warrants.
What new manufacturing initiatives has TC BioPharm announced?
TC BioPharm is developing a new manufacturing process expected to increase treatment capacity from 52 to over 1,000 patients per year while reducing costs by 85%.
What is TC BioPharm's compassionate use program?
The compassionate use program in the UK allows patients who are ineligible for clinical trials to access TC BioPharm's lead therapeutic TCB-008.
What are the company's latest strategic acquisitions?
TC BioPharm has executed non-binding letters of intent to acquire assets focused on CAR-NK cell therapies and a company developing CAR-T therapies for solid tumors and autoimmune diseases.
Where can I watch the CEO's interview on 'The Big Biz Show'?
The interview can be viewed on streaming services like Roku, iHeart Radio, and Apple Podcasts, among others.
What is TC BioPharm's position in the biopharmaceutical industry?
TC BioPharm is a leader in developing gamma-delta T cell therapies and the first to conduct phase II/pivotal clinical studies in oncology.
TC BioPharm (Holdings) plc American Depositary Shares
Nasdaq:TCBP
TCBP Rankings
TCBP Stock Data
343.79k
528.45k
0.01%
1.76%
11.35%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States of America
HOLYTOWN